Skip to main navigation

Skip to Content

Home
About Us
Clinical Pipeline
Investors & News
Contact Us

Press Releases

Keyword Search

Year

Sep 03, 2024

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024

NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Aug 06, 2024

NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity

Jul 30, 2024

NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01

Jul 11, 2024

NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July

Jun 26, 2024

NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Jun 25, 2024

NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 24, 2024

NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 22, 2024

NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Print

RSS Feeds

E-mail Alerts

IR Contacts

LinkedIn
Contact Us
Terms of Use
Privacy Policy

©2024 NeuroBo Pharmaceuticals, Inc.